Auauniversity

Advances in ADT Part II: A Guide for Urologists CME Available: https://auau.auanet.org/node/39385 LEARNING OBJECTIVES After participating in this educational activity, participants will be able to: 1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC. 2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer. 3. Facilitate discussions with patients and caregivers regarding treatment intensification for advanced prostate cancer. 4. Identify the role of combination therapy with ADT and additional systemic therapy to yield optimal survival outcomes for metastatic prostate cancer. 5. Differentiate mechanisms of action and side effects when ADT is delivered via GnRH agonists vs. antagonists. ACKNOWLEDGEMENTS Independent educational grant support provided by: Myovant Sciences LTD Pfizer, Inc.

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice CME Available: https://auau.auanet.org/node/39292 After participating in this educational activity, participants will be able to: 1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline. 2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer. 3. Define M0 CRPC and the treatment options. 4. Identify clinically meaningful endpoints in clinical trials of patients with M0 CRPC. 5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC. 6. Discuss treatment intensification in mHSPC. 7. Discuss challenges in incorporating AUA/SUO Advanced Prostate Cancer Guideline and management of advanced mHSPC and CRPC into community practice. ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: • Astellas and Pfizer, Inc. • Janssen Biotech, Inc., administered by Janssen Scientific Affai

AUA2023 Medical Student Forum

AUA2023: Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide CME Available: https://auau.auanet.org/node/38322 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/38312 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

Treatment for Hormone Sensitive Prostate Cancer CME Available: https://auau.auanet.org/node/38703 Treatment for Hormone Sensitive Prostate Cancer (2023), is an exciting new educational offering to update urologists on the latest advancements in the management of hormone sensitive prostate cancer (HSPC), including treatment intensification. This educational initiative is comprised of multiple formats, including a live virtual course, on-demand webcast, and a podcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion. At the conclusion of this activity, participants will be able to: 1. Apply the AUA Clinical Guidelines for Advanced Prostate Cancer for the treatment of HSPC. 2. Summarize the current utilization of treatment intensification in HSCP and apply appropriate treatment intensification in men with HSPC. 3. Describe the current indications, potential benefits and adverse events that may occur with use of doublet and

Update Series (2023) Lesson 21: Management of Chronic Pelvic Pain in Men Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23

AUA2023: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider CME Available: https://auau.auanet.org/node/38307 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation CME Available: https://auau.auanet.org/node/38327 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Merck & Co., Inc. Pfizer, Inc.

AUA2023: What the General Urologist Should Know about Care of Transgender Patients CME Available: https://auau.auanet.org/node/38342 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: Refractory Overactive Bladder: How To Select 3rd Line Therapies and Optimize Outcomes CME Available: https://auau.auanet.org/node/38287 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas Urovant Sciences, Inc.

AUA2023: Prostate Cancer Diagnosis CME Available: https://auau.auanet.org/node/38302 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed. CME Available: https://auau.auanet.org/node/38615 ACKNOWLEDGEMENTS This educational series is supported by an independent educational grant from AstraZeneca. After participating in this educational series, participants will be able to: 1. Delineate key factors to risk stratify patients with NMIBC and MIBC. 2. Review guidelines f

AUA2023: Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women CME Available: https://auau.auanet.org/node/38337/ ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice CME Available: https://auau.auanet.org/node/38317 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: AUA Guidelines on Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38297 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Diversity, Equity and Inclusion in Urology: What Do We Need to Know CME Available: https://auau.auanet.org/node/38332/ ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: The Changing Face of Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38292 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Contemporary Pharmacotherapy for OAB 2023 CME Available: https://auau.auanet.org/node/38282 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas Urovant Sciences, Inc. LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy. 3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB.

Live from AUA2023: Highlights in BPH is a panel discussion filmed during the 2023 AUA Annual Meeting! This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with BPH. CME Available: https://auau.auanet.org/node/38008 ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Cook Medical, LLC. Olympus Corporation of the Americas